Subhaan Mian

 Background: Opioids remain essential for treating moderate-to-severe pain, yet their clinical value is limited by opioid-induced respiratory depression (OIRD), a potentially fatal suppression of breathing that contributes to the ongoing opioid crisis.¹ Traditional mu-opioid receptor (MOR) agonists, such as morphine and fentanyl, activate G protein signaling associated with analgesia and β-arrestin-associated regulatory pathways linked to receptor internalization, hypothesized to cause tolerance, and OIRD, a life threatening risk.² This apparent separation encouraged development of G protein-biased MOR agonists intended to preserve analgesia by avoiding the recruitment of regulatory proteins while reducing respiratory depression. However, emerging evidence suggests that OIRD is not caused by a single receptor pathway alone, but by distributed respiratory network failure and differences in MOR intrinsic efficacy.^1-3

Objective: This narrative review evaluates whether biased or low-efficacy MOR agonism can minimize OIRD while maintaining analgesia, with emphasis on respiratory circuit mechanisms.

Search Methods: An online search in the PubMed database was conducted from 2020 to 2026 using the following keywords: “OIRD”, “biased agonism”, “preBötzinger complex”, and “Kölliker-Fuse nucleus”.

Results: In the preBötzinger complex (preBötC), the rhythmogenic hub for breathing, approximately half of functionally identified preBötC neurons express Oprm1, a gene encoding for opioid receptor mu 1. MOR activation produces a dual mechanism of respiratory network failure: reduced pre-inspiratory spiking, likely through GIRK-mediated neuronal hyperpolarization, and suppressed excitatory synaptic transmission through presynaptic inhibition of glutamate release. Computational modeling showed that intrinsic hyperpolarization and presynaptic suppression must occur concurrently to reproduce OIRD.⁴ Additional work expanded this model beyond the preBötC by showing that opioids suppress an excitatory pontomedullary circuit from the Kölliker-Fuse nucleus to medullary respiratory centers. This is accomplished through three convergent mechanisms: somatodendritic hyperpolarization of pontine neurons, presynaptic inhibition of glutamate release from their terminals, and postsynaptic hyperpolarization of target medullary neurons.⁵  In assays designed to reduce signal-amplification artifacts, oliceridine, PZM21, and SR-17018 showed low intrinsic efficacy across G protein and β-arrestin pathways, with therapeutic window correlating more strongly with intrinsic efficacy than with calculated bias.⁶ Clinically, oliceridine demonstrated a 39% higher C50 for respiratory depression than morphine in older volunteers and returned respiratory function to baseline five times faster. Although, CYP2D6 poor metabolizers had reduced clearance and higher exposure.⁷ Additionally, in rat models, SR14968 and SR17018 produced robust antinociception across thermal, neuropathic, and inflammatory pain models with reduced reinforcing effectiveness and no dose-dependent respiratory depression at doses exceeding the antinociceptive range.⁸

Conclusions: These studies suggest that OIRD reflects multisite respiratory circuit collapse rather than a single pathway failure. Pharmacologic evidence further challenges that notion. Safer opioid design should move beyond the idea that biased G protein signaling alone will eliminate OIRD. The reviewed literature indicates that respiratory depression arises from concurrent suppression of intrinsic neuronal excitability and synaptic communication across preBötC and pontomedullary circuits. Evidently, the improved safety profiles of oliceridine and SR-series compounds may be better explained by optimized low intrinsic efficacy rather than true signaling bias alone. Future research should refine MOR efficacy profiles, account for circuit-specific receptor signaling, and consider genetic differences in metabolism to preserve analgesia while reducing life-threatening respiratory risk.

Works Cited:

1. Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain – United States, 2022. MMWR Recomm Rep. 2022;71(3):1-95. Published 2022 Nov 4. doi:10.15585/mmwr.rr7103a1
2. Pattullo GG. Clinical implications of opioid-induced ventilatory impairment. Anaesth Intensive Care. 2022;50(1-2):52-67. doi:10.1177/0310057X211070292
3. Baldo BA, Rose MA. Mechanisms of opioid-induced respiratory depression. Arch Toxicol. 2022;96(8):2247-2260. doi:10.1007/s00204-022-03300-7
4. Baertsch NA, Bush NE, Burgraff NJ, Ramirez JM. Dual mechanisms of opioid-induced respiratory depression in the inspiratory rhythm-generating network. Elife. 2021;10:e67523. Published 2021 Aug 17. doi:10.7554/eLife.67523
5. Bateman JT, Levitt ES. Opioid suppression of an excitatory pontomedullary respiratory circuit by convergent mechanisms. Elife. 2023;12:e81119. Published 2023 Jun 14. doi:10.7554/eLife.81119
6. Gillis A, Gondin AB, Kliewer A, et al. Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Sci Signal. 2020;13(625):eaaz3140. Published 2020 Mar 31. doi:10.1126/scisignal.aaz3140
7. Simons P, van der Schrier R, van Lemmen M, et al. Respiratory Effects of Biased Ligand Oliceridine in Older Volunteers: A Pharmacokinetic-Pharmacodynamic Comparison with Morphine. Anesthesiology. 2023;138(3):249-263. doi:10.1097/ALN.0000000000004473
8. Zamarripa CA, Pareek T, Pham LM, et al. Comparison of the reinforcing, antinociceptive, and respiratory depressant effects of prototypical and G-protein biased mu-opioid receptor agonists in male and female Sprague-Dawley rats. Psychopharmacology (Berl). 2024;241(12):2453-2469. doi:10.1007/s00213-024-06690-x